Mechanistic insights into the structure-based design of a CspZ-targeting Lyme disease vaccine.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 40189575.
- Also identified by DOI 10.1038/s41467-025-58182-x and PMC identifier 11973211.
- Licence recorded as CC BY.
- The licence permits redistribution, so the abstract is shown in full and the full text is available from the publisher.
Abstract
Borrelia burgdorferi (Bb) causes Lyme disease (LD), one of the most common vector-borne diseases in the Northern Hemisphere. Here, we solve the crystal structure of a mutated Bb vaccine antigen, CspZ-YA that lacks the ability to bind to host complement factor H (FH). We generate point mutants of CspZ-YA and identify CspZ-YA<sub>I183Y</sub> and CspZ-YA<sub>C187S</sub> to trigger more robust bactericidal responses. Compared to CspZ-YA, these CspZ-YA mutants require a lower immunization frequency to protect mice from LD-associated inflammation and bacterial colonization. Antigenicity of wild-type and mutant CspZ-YA proteins are similar, as measured using sera from infected people or immunized female mice. Structural comparison of CspZ-YA with CspZ-YA<sub>I183Y</sub> and CspZ-YA<sub>C187S</sub> shows enhanced interactions of two helices adjacent to the FH-binding sites in the mutants, consistent with their elevated thermostability. In line with these findings, protective CspZ-YA monoclonal antibodies show increased binding to CspZ-YA at a physiological temperature (37 °C). In summary, this proof-of-concept study applies structural vaccinology to enhance intramolecular interactions for the long-term stability of a Bb antigen while maintaining its protective epitopes, thus promoting LD vaccine development.
Medical subject headings
- Borrelia burgdorferi
- Lyme Disease
- Lyme Disease Vaccines
- Bacterial Proteins